Cardiovascular Systems, Inc. (NASDAQ:CSII) Receives Consensus Rating of “Hold” from Brokerages

Shares of Cardiovascular Systems, Inc. (NASDAQ:CSIIGet Rating) have received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $35.00.

Several equities research analysts have recently weighed in on the stock. StockNews.com initiated coverage on shares of Cardiovascular Systems in a research report on Thursday, March 31st. They set a “hold” rating for the company. Bank of America started coverage on Cardiovascular Systems in a research report on Wednesday, March 2nd. They issued an “underperform” rating for the company.

In other news, CFO Jeffrey S. Points bought 3,000 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The stock was acquired at an average cost of $14.50 per share, with a total value of $43,500.00. Following the transaction, the chief financial officer now directly owns 109,312 shares of the company’s stock, valued at approximately $1,585,024. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.40% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Qube Research & Technologies Ltd bought a new position in shares of Cardiovascular Systems in the fourth quarter valued at $789,000. BNP Paribas Arbitrage SA lifted its position in Cardiovascular Systems by 344.6% in the 4th quarter. BNP Paribas Arbitrage SA now owns 171,228 shares of the medical device company’s stock valued at $3,216,000 after acquiring an additional 132,716 shares in the last quarter. M&T Bank Corp boosted its stake in Cardiovascular Systems by 35.7% during the 4th quarter. M&T Bank Corp now owns 16,934 shares of the medical device company’s stock valued at $318,000 after purchasing an additional 4,452 shares during the last quarter. Symmetry Investments LP bought a new stake in Cardiovascular Systems during the 4th quarter worth approximately $361,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Cardiovascular Systems by 176.9% in the third quarter. Goldman Sachs Group Inc. now owns 137,784 shares of the medical device company’s stock worth $4,524,000 after purchasing an additional 88,023 shares during the last quarter. 91.24% of the stock is owned by institutional investors and hedge funds.

Shares of CSII opened at $13.87 on Friday. The stock’s 50-day moving average price is $16.77 and its two-hundred day moving average price is $18.67. Cardiovascular Systems has a 12 month low of $13.41 and a 12 month high of $44.57. The company has a market capitalization of $565.69 million, a PE ratio of -16.51 and a beta of 0.92. The company has a current ratio of 5.28, a quick ratio of 4.58 and a debt-to-equity ratio of 0.08.

Cardiovascular Systems (NASDAQ:CSIIGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The medical device company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The company had revenue of $56.22 million for the quarter, compared to analyst estimates of $57.38 million. Cardiovascular Systems had a negative return on equity of 12.43% and a negative net margin of 13.29%. The firm’s quarterly revenue was down 11.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.15) earnings per share. Equities research analysts predict that Cardiovascular Systems will post -0.91 EPS for the current fiscal year.

Cardiovascular Systems Company Profile (Get Rating)

Cardiovascular Systems, Inc, a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

Read More

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.